National Healthcare director granted 7,500 options
National Healthcare Corp director Lisa Piercey received a grant of stock options as compensation.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
National Healthcare Corp director Lisa Piercey received a grant of stock options as compensation. On May 7, 2026, she was awarded options to purchase 7,500 shares of common stock at an exercise price of $171.42 per share, expiring on May 6, 2030. The options were granted under the company’s 2020 Omnibus Equity Incentive Plan, with no cash paid at grant, and leave her holding 7,500 options following the transaction.
Insider Trade Summary
Grant/Award: 7,500 shares
Grant/Award
1 txn
Insider
Piercey Lisa
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Option to Purchase Common Stock [2026 Grant] | 7,500 | $0.00 | $0.00 |
Holdings After Transaction:
Option to Purchase Common Stock [2026 Grant] — 7,500 contracts (Direct)
Footnotes (1)
- F1. These stock options were granted pursuant to the 2020 Omnibus Equity Incentive Plan on May 7, 2026. The grant and exercise of these stock options are exempt from Section 16(b) pursuant to Rule 16b-3(d).
Key Figures
Options granted: 7,500 options
Exercise price: $171.42 per share
Expiration date: May 6, 2030
+2 more
5 metrics
Options granted
7,500 options
Stock options to purchase common stock granted May 7, 2026
Exercise price
$171.42 per share
Conversion or exercise price of granted options
Expiration date
May 6, 2030
Option expiration date for this grant
Options after transaction
7,500 options
Total derivative securities following the transaction
Grant price paid
$0.00 per option
Transaction price per option at grant
Key Terms
Option to Purchase Common Stock, 2020 Omnibus Equity Incentive Plan, Rule 16b-3(d), Section 16(b), +1 more
5 terms
Option to Purchase Common Stock financial
"security_title: Option to Purchase Common Stock [2026 Grant]"
2020 Omnibus Equity Incentive Plan financial
"These stock options were granted pursuant to the 2020 Omnibus Equity Incentive Plan"
Rule 16b-3(d) regulatory
"exempt from Section 16(b) pursuant to Rule 16b-3(d)"
Rule 16b-3(d) is a narrow SEC safe-harbor that shields company insiders (officers, directors and large shareholders) from liability for short‑swing profits when their buys or sells of company stock are made under a pre-established, written plan or contract that removes the insider’s ability to time trades. For investors, this matters because it permits predictable, automated insider transactions — like scheduled sales for diversification or payroll withholding — without triggering forced disgorgement, so such planned trades are treated differently from opportunistic insider trading.
Section 16(b) regulatory
"The grant and exercise of these stock options are exempt from Section 16(b)"
A federal rule that requires company insiders—like officers, directors and large shareholders—to return any profits made from buying and selling the company’s stock within a six-month window. It matters to investors because it discourages short-term trades that could exploit non-public information and helps protect outside shareholders by creating a simple, enforceable way to recover unfair gains, much like a rule stopping someone from flipping a limited-edition item for quick profit after getting early access.
derivative securities financial
"derivativeTransactionCount: 1, total derivative securities following the transaction"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did NHC director Lisa Piercey report on her latest Form 4?
Lisa Piercey reported a grant of stock options from National Healthcare Corp. She received options for 7,500 shares of common stock as part of equity compensation, rather than buying or selling shares in the open market, under the company’s 2020 Omnibus Equity Incentive Plan.
How many National Healthcare Corp (NHC) options did Lisa Piercey receive?
Lisa Piercey received 7,500 stock options linked to National Healthcare Corp common shares. These options give her the right to buy up to 7,500 shares at a fixed exercise price, providing potential future ownership if she chooses to exercise them before the stated expiration date.
What is the exercise price and term of Lisa Piercey’s NHC stock options?
The options have an exercise price of $171.42 per share and expire on May 6, 2030. This means she can purchase National Healthcare Corp common stock at $171.42 any time before that date, subject to the plan’s vesting and exercise conditions disclosed elsewhere.
Was Lisa Piercey’s NHC option grant an open-market purchase or compensation award?
The transaction was a compensation-related award, not an open-market purchase. It is coded as a grant or award acquisition under Form 4 rules, showing options issued at no cost at grant, consistent with equity incentives provided under the 2020 Omnibus Equity Incentive Plan.
How many National Healthcare Corp options does Lisa Piercey hold after this grant?
Following this transaction, Lisa Piercey holds 7,500 stock options reported for National Healthcare Corp. The filing shows total derivative securities following the transaction equal to 7,500 options, all directly owned, reflecting her position under the company’s equity incentive arrangements.
AI-generated analysis. How Rhea-AI works. Not financial advice.
